Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in Early Psychosis
NCT02504151Phase 2Completed
- Sponsor
- Yale University
- Start
- Jan 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol in schizophrenia, schizoaffective disorder, sponsored by Yale University. Started Jan 2016; status: completed.
02
Drugs
cannabidiol
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02504151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504151.